Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of September, 2023

Commission File Number 001-39670




(Translation of registrant’s name into English)



6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐





On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 13, 2023, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended September 30, 2023, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:



   Ordinary Shares
     Volume Weighted
Average Price Paid
per Ordinary Share
     Highest Price Paid      Lowest Price Paid  

September 1, 2023

     35,954        200.06p        201.50p        197.80p  

September 4, 2023

     26,557        202.06p        203.50p        200.50p  

September 5, 2023

     34,972        204.04p        206.00p        200.00p  

September 6, 2023

     34,183        199.03p        203.00p        196.00p  

September 7, 2023

     34,282        201.15p        205.00p        198.20p  

September 8, 2023

     31,932        200.45p        202.00p        198.20p  

September 11, 2023

     31,688        202.20p        204.00p        201.00p  

September 12, 2023

     35,193        207.39p        210.00p        205.00p  

September 13, 2023

     34,874        207.80p        209.50p        204.50p  

September 14, 2023

     33,277        209.59p        212.50p        206.50p  

September 15, 2023

     4,718        215.91p        216.00p        215.00p  

September 18, 2023

     13,710        222.99p        223.00p        222.50p  

September 19, 2023

     47,512        227.38p        228.50p        225.00p  

September 20, 2023

     49,098        227.01p        231.00p        225.00p  

September 21, 2023

     50,805        223.69p        226.50p        222.00p  

September 22, 2023

     50,220        218.28p        221.50p        213.50p  

September 25, 2023

     52,782        204.27p        213.50p        201.50p  

September 26, 2023

     51,042        201.47p        205.50p        200.00p  

September 27, 2023

     52,952        200.99p        203.50p        195.40p  

September 28, 2023

     52,040        186.17p        192.80p        180.40p  

September 29, 2023

     53,042        185.00p        190.00p        181.00p  

During the month ended September 30, 2023, the Company repurchased an aggregate of 810,833 Ordinary Shares. As of September 30, 2023, the Company’s issued share capital was 289,468,159 shares, 14,929,154 of which were held in treasury, resulting in total voting rights in the Company of 274,539,005 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

September 1, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4887228.html

September 4, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4888692.html

September 5, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4890135.html

September 6, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4891649.html

September 7, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4893157.html

September 8, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4894579.html

September 11, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4896110.html

September 12, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4897624.html

September 13, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4899101.html

September 14, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4900554.html

September 15, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4902098.html

September 18, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4903618.html

September 19, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4905167.html

September 20, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4906648.html

September 21, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4908196.html

September 22, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4909642.html

September 25, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4911197.html

September 26, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4912791.html

September 27, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4914423.html

September 28, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4916154.html

September 29, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4917869.html


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: October 3, 2023   By:  

/s/ Daphne Zohar

    Name:   Daphne Zohar
    Title:   Chief Executive Officer